
    
      A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of
      the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor
      Antagonist, Casopitant, administered in Combination with ZOFRAN and Dexamethasone for
      Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly
      Emetogenic Cisplatin-Based Chemotherapy
    
  